All Articles

Dave Cantin Group's strategic hire of Nate Klebacha signals a new era of data-driven M&A as dealership consolidation continues to accelerate.

Savaria’s consistent dividend signals robust financial health, tapping into a growing market driven by powerful demographic shifts and the 'aging in place' trend.

NEO Home Loans adopts Better's AI to slash mortgage decision times, signaling a new era of speed. But what are the risks behind the efficiency?

Rutgers Business School is overhauling its MBA in Professional Accounting, cutting costs and adding critical tech skills to prepare a new generation of CPAs.

A major distribution shift sees Southern Glazer’s expand its Pernod Ricard deal into TX, LA, and OK, reshaping the competitive landscape for spirits.

Richtech Robotics hires top-tier auditor CBIZ, citing a strategic shift, but SEC filings reveal a prior warning about a “material weakness” in controls.

PetClaw AI launches a new desktop agent that works for you 24/7, promising ultimate productivity. But can its local-first privacy model win in a crowded field?

Amid a lawsuit, Health Gorilla releases evidence it says proves a partner misrepresented its use of patient data, igniting a debate on trust in health tech.

Winning a top FinTech award, Bags.fm's model has driven $5B in volume, but its innovation comes with the high risks of a volatile new market.

Apple iSports hires innovation guru Ian Wilding to guide its Nasdaq ambitions, a move underscored by a corrective press release signaling growing pains.

A new pilot in LA proves that smart design, not sacrifice, is the key to massive water savings and a better quality of life at home.

Old Forester unveils its High Angels' Share Rye, a limited 117 Series release using extreme maturation science to create a hyper-concentrated whiskey.

Trian Fund Management publicly rejects Victory Capital’s higher offer for Janus Henderson, citing 'significant value destruction' and setting up a showdown.

With a history of billion-dollar deals, Mark Altmeyer takes the helm at ReproNovo, aiming to commercialize its promising fertility and women's health pipeline.

RenovoRx sets a key update call, juggling early RenovoCath device sales with its pivotal Phase III pancreatic cancer trial, a beacon for patients.

China Natural Resources, with a tiny $5M market cap, plans to buy a majority stake in AI startup HooRii for $40M, a high-risk pivot for survival.

A brain aneurysm device successful in Europe has treated its first U.S. patient in a pivotal trial, promising to expand treatment options for thousands.

LA-based Lucky Break PR signals major East Coast ambitions, hiring a seasoned leader to conquer the competitive New York communications market.

XPPen's new Artist Pro 27 (Gen 2) packs a 4K 120Hz screen, elite color accuracy, and a full suite of accessories to challenge the professional market.

IntraBio's landmark FDA submission for levacetylleucine offers the first glimmer of an approved therapy for the devastating rare disease Ataxia-Telangiectasia.